The Effect of Sample Medication Use on Subsequent Anti-VEGF Agent Selection for Neovascular Age-Related Macular Degeneration
| Autor: | Joan W. Miller, Mary E. Aronow, Tedi Begaj, John B Miller, Lucy H. Young, Rachel M. Huckfeldt, Jan A. Kylstra, Demetrios G. Vavvas, Deeba Husain, Dean Eliott, David M. Wu, Shizuo Mukai, Leo A. Kim, Evan Chen, Sachi Patil, Lucia Sobrin, Karen M Wai, Ravi Parikh, Evangelos S. Gragoudas, Nimesh A. Patel |
|---|---|
| Rok vydání: | 2022 |
| Předmět: |
Vascular Endothelial Growth Factor A
medicine.medical_specialty Visual acuity Bevacizumab Recombinant Fusion Proteins Angiogenesis Inhibitors Macular Degeneration Age related Internal medicine Ranibizumab medicine Humans Aflibercept Retrospective Studies Anti vegf business.industry General Medicine Macular degeneration medicine.disease Ophthalmology Receptors Vascular Endothelial Growth Factor Intravitreal Injections medicine.symptom business medicine.drug Cohort study |
| Zdroj: | Seminars in Ophthalmology. 37:902-908 |
| ISSN: | 1744-5205 0882-0538 |
| DOI: | 10.1080/08820538.2022.2107398 |
| Popis: | Purpose: To examine the effect of medication sample use (ranibizumab or aflibercept) on future anti-vascular endothelial growth factor (VEGF) agent selection in neovascular age-related macular degeneration (nvAMD). Design: Retrospective cohort study. Methods: nvAMD patients who underwent an initial anti-VEGF injection with a sample medication were compared to nvAMD control patients who never received a medication sample. Charts from 2017 through 2020 were reviewed for data regarding demographics, anti-VEGF agent selection, and visual acuity outcomes for both groups. Anti-VEGF agent selection for the first four injections and at one year were examined in both the sample and control groups. Results: Adherence to the initial agent was high between first and subsequent injections (2nd, 3rd, 4th injection, and 1 year) in both sample (96.2%, 95.9%, 91.9%, 93.4%, respectively) and control groups (98.1%, 94.2%, 94.9%, 87.8%, respectively). Bevacizumab usage was significantly lower among eyes receiving samples relative to controls at the second (1.9% vs. 38.7%, p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|